Table 1.
Characteristics of 265 patients with ILD according to ANCA status*
| Characteristics | Total (N = 265) | ANCA positive (n = 26) | ANCA negative (n = 239) |
|---|---|---|---|
| Age, mean (SD), years | 69.3 (10.6) | 66.5 (9.7) | 69.6 (10.7) |
| Male sex, n (%) | 150 (56.6) | 13 (50.0) | 137 (57.3) |
| Ethnicity, n (%) | |||
| White | 211 (79.6) | 19 (73.1) | 192 (80.3) |
| Native Hawaiian or other Pacific Islander | 6 (2.3) | 1 (3.8) | 5 (2.1) |
| Hispanic or Latino/a | 8 (3.0) | 3 (11.5) | 5 (2.1) |
| Black or African American | 9 (3.4) | 0 | 9 (3.8) |
| Asian | 29 (10.9) | 3 (11.5) | 26 (10.9) |
| Other | 2 (0.8) | 0 | 2 (0.8) |
| Any smoking history, n (%) | 179 (67.5) | 16 (61.5) | 163 (68.2) |
| Multiple autoantibodies, n (%) | 70 (26.4) | 18 (69.2) | 52 (21.8) |
| Rheumatoid factor | 50 (18.9) | 11 (42.3) | 39 (14.7) |
| Antinuclear autoantibodies | 51 (19.2) | 5 (19.2) | 46 (19.2) |
| Anti–Scl‐70 | 9 (3.4) | 2 (7.7) | 7 (2.9) |
| Anti‐SSA/Ro‐52 and/or anti‐SSB | 32 (12.1) | 2 (7.7) | 30 (12.6) |
| Myositis autoantibodies | 57 (21.5) | 4 (15.4) | 53 (22.2) |
| Previous autoimmune disease, n (%) | 77 (29.1) | 20 (76.9) | 57 (23.4) |
| Final ILD clinical diagnosis, n (%) | |||
| IPF | 88 (33.2) | 3 (11.5) | 85 (35.6) |
| iNSIP | 26 (9.8) | 2 (7.7) | 26 (10.9) |
| RB‐ILD | 8 (3.0) | 0 | 8 (3.3) |
| DIP | 12 (4.5) | 0 | 12 (5.0) |
| COP | 10 (3.8) | 3 (11.5) | 7 (2.9) |
| LIP | 3 (1.1) | 0 | 3 (1.3) |
| IPPFE | 1 (0.4) | 0 | 1 (0.4) |
| Unclassifiable ILD | 63 (23.8) | 2 (7.7) | 61 (25.5) |
| SRIF | 5 (1.9) | 0 | 5 (2.1) |
| CTD‐ILD | 38 (14.3) | 6 (23.1) | 32 (13.4) |
| Others | 11 (4.2) | 10 (38.5) | 1 (0.4) |
| Vasculitis, n (%) | |||
| None | 247 (93.2) | 9 (34.6) | 238 (99.6) |
| MPA | 11 (4.2) | 11 (42.3) | 0 |
| GPA | 6 (2.3) | 6 (23.1) | 0 |
| EGPA | 1 (0.4) | 0 | 1 (0.4) |
Myositis autoantibodies include anti‐SRP, anti‐PmScl75/100, anti‐Ku, anti‐Jo1, anti‐PL7, anti‐PL12, anti‐EJ, anti‐OJ, anti‐Ro52, anti‐MDA‐5, anti‐TIF1‐γ, anti‐Mi2a/b, anti‐NXP2, and anti‐SAE. ANCA, antineutrophil cytoplasmic autoantibody; COP, cryptogenic organizing pneumonia; CTD‐ILD, connective tissue disease–associated interstitial lung disease; DIP, desquamative interstitial pneumonia; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; ILD, interstitial lung disease; iNSIP, idiopathic nonspecific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; IPPFE, idiopathic pleuroparenchymal fibroelastosis; LIP, lymphoid interstitial pneumonia; MPA, microscopic polyangiitis; RB‐ILD, respiratory bronchiolitis–interstitial lung disease; SRIF, smoking‐related interstitial fibrosis.